Get the Stockscreener App
1.93
5.85%
-0.12
After Hours:
1.92
-0.01
-0.52%
Anebulo Pharmaceuticals Inc stock is traded at $1.93, with a volume of 18,968.
It is down -5.85% in the last 24 hours and up +0.52% over the past month.
Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company. It is developing novel solutions for people suffering from cannabinoid overdose and substance addiction. The product candidate, ANEB-001, is intended to reverse the negative effects of cannabinoid overdose within 1 hour of administration. The signs and symptoms of cannabinoid overdose range from profound sedation to anxiety and panic to psychosis with hallucinations.
See More
Previous Close:
$2.05
Open:
$2.11
24h Volume:
18,968
Relative Volume:
2.06
Market Cap:
$53.16M
Revenue:
-
Net Income/Loss:
$-10.49M
P/E Ratio:
-4.1064
EPS:
-0.47
Net Cash Flow:
$-9.58M
1W Performance:
-13.06%
1M Performance:
+0.52%
6M Performance:
-32.75%
1Y Performance:
-36.82%
1-Day Range:
$1.89
$2.14
1-Week Range:
$1.80
$2.29
52-Week Range:
$1.62
$3.6099
Anebulo Pharmaceuticals Inc Stock (ANEB) Company Profile
Name
Anebulo Pharmaceuticals Inc
Sector
Industry
Phone
737 203 5270
Address
JFL CAPITAL MANAGEMENT, LAKEWAY
Anebulo Pharmaceuticals Inc Stock (ANEB) Latest News
Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Short Interest Up 27.7% in September - Defense World
Anebulo Pharmaceuticals reports Q4 EPS (5c) vs. (10c) last year - TipRanks
Anebulo Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended June 30, 2024 - Marketscreener.com
Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Recent Updates - StockTitan
Njabulo Blom set to boost Kaizer Chiefs midfield - FarPost
Kirkland Advises Luminate Capital Partners on its Investment in AbsenceSoft - Legal Desire News Network
Amway marks “Amway Health Run 2024” to celebrate Nutrilite’s 90th anniversary - Nation Thailand
Market Movers Monday: KAVL, PRSO, TGL, PNPNF, NVVE Surge on Breaking Developments - openPR
'Survival instinct kicked in': Survivor of Five Points South mass shooting speaks out - Alabama's News Leader
Langley double-shooting kills one, injures another - CityNews Vancouver
Here's Why We're Watching Anebulo Pharmaceuticals' (NASDAQ:ANEB) Cash Burn Situation - Yahoo Finance
One dead, one wounded after 2 men shot in Langley - MSN
Anebulo Pharmaceuticals Secures NIH Grant for Emergency Cannabis Antidote Development - BP Journal
Indian Super League: Anwar Ali cleared to play for East Bengal, say reports - Scroll.in
Anwar Ali receives NOC from AIFFWhen will he make East Bengal debut? - myKhel
Aligos' fatty liver disease treatment meets main goal in mid-stage study - XM
AmaZulu coach Pablo Franco defends Veli Mothwa as Kaizer Chiefs game looms - IOL
Banzai International, Inc. (NASDAQ:BNZI) Sees Large Growth in Short Interest - Defense World
Global X Active Canadian Dividend ETF Common (TSE:HAL) Stock Passes Above 200 Day Moving Average of $20.01 - Defense World
Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Sees Significant Growth in Short Interest - MarketBeat
'Very stupid': Man who helped supply gun later used in Auckland CBD shooting sentenced - New Zealand Herald
Driver arrested in Muse homicide wants assault charge dropped - Bowling Green Daily News
Josue is now a KL City legend - New Straits Times
Scilex Holding (NASDAQ:SCLX) Stock Quotes, Forecast and News Summary - Benzinga
Short Interest in Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Declines By 5.3% - Defense World
XORTX Therapeutics Inc ($XRTX): Pioneering New Treatments for Kidney Disease with a Precision-Medicine Approach - BP Journal
Short Interest in Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Declines By 8.3% - MarketBeat
Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Short Interest Update - Defense World
Anebulo Pharmaceuticals Announces New CEO - GuruFocus.com
Can Actinium Pharmaceuticals (ATNM) bounce back from the Regulatory Hurdles - BP Journal
Anebulo Pharmaceuticals (NASDAQ:ANEB) Shares Down 4% - Defense World
After-Market Stock Rise In Anebulo (ANEB) Indicates Potential Shift In Investor Sentiment - Stocks Telegraph
Is today’s surge in Dermata Therapeutics (DRMA) justified ? - BP Journal
Anebulo Pharmaceuticals receives NIDA grant for drug development By Investing.com - Investing.com Canada
Anebulo Pharmaceuticals receives NIDA grant for drug development - Investing.com
Anebulo Pharmaceuticals Awarded NIDA Grant for its Investigational IV Treatment for Acute Cannabis-Induced Toxic Effects - Winchester Herald Chronicle
Anebulo Pharmaceuticals Awarded NIDA Grant for its Investigational IV Treatment for Acute Cannabis-Induced Toxic Effects - StockTitan
Anebulo Pharmaceuticals Awarded NIDA Grant for its Investigational IV Treatment for Acute Cannabis-Induced Toxic Effects - Business Wire
Adlai Nortye Ltd. (NASDAQ:ANL) Sees Significant Drop in Short Interest - American Banking and Market News
Tate & Lyle (LON:BD15) Stock Price Passes Above 200 Day Moving Average of $99.00 - American Banking and Market News
NASDAQ – Stock Price, Charts & News Today - BNN Bloomberg
Financial Review: Palladyne AI (PDYN) versus Its Rivals - Defense World
Financial Contrast: Anebulo Pharmaceuticals (NASDAQ:ANEB) vs. IO Biotech (NASDAQ:IOBT) - Defense World
Has Anebulo Pharmaceuticals (ANEB) Outpaced Other Medical Stocks This Year? - Yahoo Movies Canada
Alumis Inc (ALMS) Takes a Bold Step Forward with Its Initial Public Offering and sinks on debut - BP Journal
U.S. shares mixed at close of trade; Dow Jones Industrial Average down 0.21% - MSN
Genprex Issues Stockholder Letter and Provides 2024 Corporate Update - Quantisnow
Genprex Announces Groundbreaking Data from Non-Human Primate Study Evaluating Novel Gene Therapy to Treat ... - Quantisnow
Genprex CEO Commends FDA's Initiative to Accelerate Approval Process for Gene Therapies - Quantisnow
Best Stocks Under $5 Right Now • BenzingaInvesting - Benzinga
Top Performing Stocks • Benzinga - Benzinga
Anebulo Pharmaceuticals Inc Stock (ANEB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):